Quel est le prix pour Algernon Pharmaceuticals Inc. (AGN)

Le prix pour Algernon Pharmaceuticals Inc. (AGN) est $0.29357476

Quelle est la capitalisation boursière pour Algernon Pharmaceuticals Inc. (AGN)

La capitalisation boursière pour Algernon Pharmaceuticals Inc. (AGN) est $1.02M

Algernon Pharmaceuticals Inc. (AGN) Prix et Capitalisation Boursière

Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Prix pour AGN	L’actif B	La capitalisation boursière de B	Résultats
$1,565,333 $1.02M	NVDA	$5.452T	+533,197,384.77%
$1,289,717 $1.02M	AAPL	$4.492T	+439,314,586.30%
$1,195,854 $1.02M	GOOG	$4.165T	+407,342,177.38%
$1,055,547 $1.02M	MSFT	$3.676T	+359,549,441.12%
$813,420 $1.02M	AMZN	$2.833T	+277,073,973.72%

Prix pour AGN

L’actif B

La capitalisation boursière de B

Résultats

$1,565,333 $1.02M